CD38 and Miyoshi myopathy: The results of a Phase I first-in-human 89Zr-DFO-daratumumab PET/CT imaging study in six MM patients demonstrated successful whole-body PET visualization of MM with focal tracer uptake in previously known as well as unknown sites of osseous myeloma, consistent with successful CD38-targeted immunoPET imaging of myeloma in human patients [92].